<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808262</url>
  </required_header>
  <id_info>
    <org_study_id>TNF-K-001</org_study_id>
    <nct_id>NCT00808262</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease</brief_title>
  <official_title>A Phase I/II, Open-label, Escalating Dose, &quot;Optimal Two-stage&quot;, Study of TNFα-Kinoid (TNF- K) Immunization in Crohn's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovacs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovacs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and the immune response induced by active immunization through a&#xD;
      TNFa kinoid in patients with Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Whole study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response</measure>
    <time_frame>Day 38</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>TNFa Kinoid dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNFa Kinoid dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNFa Kinoid dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TNFa Kinoid</intervention_name>
    <description>TNFa kinoid at days 0, 7, 28</description>
    <arm_group_label>TNFa Kinoid dose 1</arm_group_label>
    <arm_group_label>TNFa Kinoid dose 2</arm_group_label>
    <arm_group_label>TNFa Kinoid dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have Active Crohn's Disease, as defined by a Crohn's Disease Activity&#xD;
             Index (CDAI) score of &gt;220 but ≤400, with active Crohn's disease of ileum and/or colon&#xD;
             (Other areas may be involved if ileum and/or colon are also involved)based upon either&#xD;
             endoscopic, histologic and/or radiographic evidence&#xD;
&#xD;
          -  Patients with active disease despite treatment with 5-ASAs or sulfasalazine,&#xD;
             corticosteroids (prednisone, budesonide, other), AZA or 6-MP or cyclosporine or MTX or&#xD;
             Tacrolimus, ; OR intolerant of 5-ASAs or sulfasalazine; or intolerant of antibiotics;&#xD;
             or intolerant of corticosteroids (prednisone, budesonide, other); or intolerant of AZA&#xD;
             or 6-MP or cyclosporine or MTX or Tacrolimus&#xD;
&#xD;
          -  Patients might have previously responded to any prior anti-TNF agents and then lost&#xD;
             response OR might be intolerant of any prior anti-TNF agents&#xD;
&#xD;
          -  Positive skin reaction to challenge with Candida antigens&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of tuberculosis or positive chest X ray or positive purified protein&#xD;
             derivative skin test or positive interferon gamma TB assay&#xD;
&#xD;
          -  Signs or symptoms of clinically significant stricture of bowel.&#xD;
&#xD;
          -  Total parenteral nutrition or elemental diet required for treatment of disease or&#xD;
             support of short bowel syndrome&#xD;
&#xD;
          -  Presence of an enteric stoma&#xD;
&#xD;
          -  Imminent or urgent surgery required for infection, abscess, bleeding or any other&#xD;
             cause relating to their Crohn's Disease or other condition&#xD;
&#xD;
          -  History of malignancy. However, subjects with basal call carcinomas or less than 3&#xD;
             squamous cell carcinomas are allowed&#xD;
&#xD;
          -  History of asthma or serious allergic condition (including history of seafood allergy)&#xD;
&#xD;
          -  Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g.,&#xD;
             pneumonia, septicemia) within the 3 months prior to the first dose of study drug&#xD;
&#xD;
          -  History of opportunistic infection excluding oral candidiasis on steroids&#xD;
&#xD;
          -  Enteric infection as evidenced by positive stool C&amp;S, O&amp;P and C. difficile obtained&#xD;
             during screening&#xD;
&#xD;
          -  Any significant or decompensated cardiac, neurologic, liver, pulmonary or renal&#xD;
             disease&#xD;
&#xD;
          -  History of lymphoproliferative disorders&#xD;
&#xD;
          -  Clinically significant abnormal hematology values, as determined by the investigator,&#xD;
             for hematocrit, hemoglobin, white blood cell count or platelets&#xD;
&#xD;
          -  Clinically significant abnormal blood chemistry values as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Current significant drug or alcohol abuse as determined by the investigator&#xD;
&#xD;
          -  Positive for hepatitis C antibody or positive for hepatitis B surface antigen (HbsAg)&#xD;
             or HIV infection&#xD;
&#xD;
          -  Surgery within the previous 3 months (other than minor cosmetic surgery or minor&#xD;
             dental procedures)&#xD;
&#xD;
          -  Participation in a clinical study (including previous participation in this study)&#xD;
             within the previous 4 months&#xD;
&#xD;
          -  Had a primary non-response to any prior anti-TNF agents as defined by the investigator&#xD;
             OR received any prior anti-TNF agents within the past 8 weeks prior to study entry&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Vandepapeliere, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neovacs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durbanville Medi-Clinic</name>
      <address>
        <city>Cape Town</city>
        <state>Cape</state>
        <zip>7550</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel Port Elizabeth</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmovs Parexel</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel George</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pierre Vandepapeliere, CMO</name_title>
    <organization>Neovacs SA</organization>
  </responsible_party>
  <keyword>anti-TNFa</keyword>
  <keyword>immunization</keyword>
  <keyword>kinoid</keyword>
  <keyword>crohn's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

